& Option Pit
Good day, 360!
Here are some of our top movers today. And please join us in Market Masters LIVE TDOAY at 1EST for spotting squeeze plays 🔥. Be there!
FOCUS LIST🔎
EVOK – Up over 20% in pre after announcing listing of new GIMOTI® patent in FDA Orange Book
YOUL – Up over 25% in pre after yesterday announcing intent to acquire four companies to strengthen market position in blue-collar talent services
THAR – Up over 45% in pre after yesterday reporting Pharmacokinetic simulation results for TH104 as Prophylaxis against respiratory depression from fentanyl and ultrapotent opioids, highlighting potential superiority over existing treatments
*together with Option Pit
⏰Today At 1PM ET!⏰
Advance Notice AI Reveal
Squeeze Alerts On Sub $20 Stocks BEFORE They Develop
Attendees Can Stop Guessing
HOTLIST🔥
EVOK – Up over 20% in pre after announcing listing of new GIMOTI® patent in FDA Orange Book
Evoke Pharma, Inc. (EVOK) is a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray.
In the pre-market this morning, the company announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book”.
Shares of EVOK traded up over 20% in the pre-market in reaction to the news.
The $7 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $7.50, $7.75, $8, $8.50 and then the pre-market high at $9. Beyond that, $9.88, $10 and $12 come into play.
Below $7, targets to the downside are $6.50, $6 and then a gap fill at $5.83.
YOUL – Up over 25% in pre after yesterday announcing intent to acquire four companies to strengthen market position in blue-collar talent services
Youlife Group Inc. (YOUL) is a leading blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China.
In the pre-market yesterday, the company announced that it has entered into a non-binding term sheets with the controlling shareholders of four companies to acquire 100% equity interests in the following entities:
Jiangsu Youlan Network Technology Co., Ltd
Hubei Joins Hands with Tongcheng Information Technology Co., Ltd
Guangxi Jiade Human Resources Service Co., Ltd
Lijiang Bona Vocational Skills Training Co., Ltd
The four target companies bring complementary expertise and regional influence across internet recruitment services, software and AI developments, human resource services, and vocational training.
Shares of YOUL traded down 8% yesterday on a weak market day despite the news and then traded up over 25% in the pre-market this morning.
The $1.85 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $2, $2.20, $2.40, $2.60, $2.68 and then the pre-market high at $2.72.
Beyond that, $2.86, $3, $3.20 and then $3.72 come into play.
Below $1.85, targets to the downside are $1.80, $1.70, $1.60 and then a gap fill at $1.52.
*sponsored by Superhuman AI
Find out why 1M+ professionals read Superhuman AI daily.
In 2 years you will be working for AI
Or an AI will be working for you
Here’s how you can future-proof yourself:
Join the Superhuman AI newsletter – read by 1M+ people at top companies
Master AI tools, tutorials, and news in just 3 minutes a day
Become 10X more productive using AI
Join 1,000,000+ pros at companies like Google, Meta, and Amazon that are using AI to get ahead.
THAR – Up over 45% in pre after yesterday reporting Pharmacokinetic simulation results for TH104 as Prophylaxis against respiratory depression from fentanyl and ultrapotent opioids, highlighting potential superiority over existing treatments
Tharimmune, Inc. (THAR) is a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and unmet medical needs.
In the pre-market yesterday, the company announced positive results from a recent pharmacokinetic (PK) simulation analysis of its lead clinical asset, TH104, a buccal film formulation of nalmefene. The results reinforce the potential of TH104 as a prophylactic countermeasure for military personnel and chemical incident responders who may be exposed to high-potency opioids, including weaponized fentanyl and its analogues.
Fentanyl and related compounds pose national security threats due to their high potency and the potential for a devastating mass casualty incident if weaponized. There is a critical need for countermeasures that can be administered proactively, prior to potential exposure, to prevent or mitigate the rapid onset of respiratory and nervous system depression from these potent agents.
Shares of THAR closed up yesterday over 200% in reaction to the news and traded up another 45% in the pre-market this morning.
The $4.80 level acted as support in the after-hours and pre-market and will be an important level to watch.
Above it, targets to the upside are $5, $5.60, $5.75, $6 and then the $6.18. Beyond that $6.50, $7.50, $8.
Below $4.80, targets to the downside are $4.60, $4 a gap fill at $3.59 with $3.15, $3, $2.20 and then $1.40.
MARKET NEWS 📰
DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). Full disclaimer: https://bullseyealerts.com/disclaimer/
SPONSORED CONTENT & COMPENSATION: You should assume we receive compensation for any non-SV purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies (“Clients”). We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.
CLIENT CONTENT: SV is not responsible for any content hosted on Client sites; it is the Client’s responsibility to ensure compliance with applicable laws.
NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content, regardless of characterization as “educational,” should be considered promotional and subject to disclosed conflicts of interest. Do NOT rely on this as personalized investment advice. SV strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS NOT TYPICAL: Past performance, testimonials, and historical results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Past newsletters, marketing materials, track records, case studies, and promotional content should NOT be relied upon as indication of future performance. Market conditions, regulatory environments, and individual circumstances vary significantly over time. Actual results will vary widely given factors such as experience, skill, risk mitigation practices, market dynamics and capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
REGULATORY STATUS: Neither SV nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
HIGH-RISK SECURITIES: Securities discussed may be penny stocks, small-cap stocks, cryptocurrencies, options, or other highly speculative investments subject to extreme price volatility, rapid and substantial price movements, limited liquidity, regulatory changes, and potential total loss of value. Market conditions can change rapidly and unpredictably.
LEGAL: In any legal action arising from or related to SV services or these terms, SV shall be entitled to recover attorneys’ fees, costs, and disbursements in addition to any other relief.
